The Foundation for Women & Girls with Blood Disorders is proud to announce its upcoming Friday Satellite Symposium preceding the 57th American Society of Hematology (ASH) annual meeting: 

An In-Depth Look at Emerging Science and Technology to Improve the Lives of Women with Blood Disorders - December 4th - 7am-11am, The Hyatt Regency Orlando, Regency Ballroom V, Orlando, FL

Reserve your space early. Register HERE.


This symposium will highlight the potential impact of emerging technologies and recent therapeutic advances on the diagnosis and treatment of women with blood disorders. Speaking from comprehensive, multidisciplinary perspectives, experts will update participants on the application of technological advances in pre-implantation and prenatal diagnosis of blood disorders; provide insight into the research pipeline for novel diagnostics and the expanding role of telemedicine in this population; and discuss the impact of novel therapeutics for inherited blood disorders on adolescent female and maternal/fetal health.

Joint Accreditation Statement 

This session is jointly provided by the Duke University Health System Department of Clinical Education and Professional Development and the Foundation for Women & Girls with Blood Disorders. 

          

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education and Professional Development and the Foundation for Women & Girls with Blood Disorders for the advancement of patient care. The Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the health care team.

 

Learning Objectives:

At the conclusion of this activity, participants should be able to:

  • Identify new technologies available to correctly diagnose at-risk fetuses, including preimplantation genetic diagnosis, chorionic villus sampling, amniocentesis and non-invasive prenatal screening
  • Define and apply strategies that remove barriers to early-stage technology development, implementation and integration into daily practice to benefit female patients with blood disorders
  • Identify and apply telehealth resources to support sickle cell patients and women with other blood disorders
  • Recognize and manage the range of complications occurring with pregnancy and the postpartum period in women with rare bleeding disorders (RBDs); and appropriately apply available new therapeutics to this management
  • Describe and apply the NIH National Heart Lung and Blood Institute recommendations (level 1) for hydroxyurea use in sickle cell disease
  • Describe and manage the challenges of anticoagulant therapy in pregnant women and teenage girls

Agenda:

The activity begins with breakfast and registration at 6:45 AM, and then is followed by:

  • 7:00 - 7:10 AM - Welcome/Introduction (Andra H. James, MD, MPH and Donna DiMichele, MD)

Emerging Technologies: Improving Diagnosis and Access to Care

  • 7:10 - 7:45 AM - Topic 1: Preimplantation and Prenatal Diagnosis of Inherited Blood disorders: Latest Technologies (Kristin Paulyson Nuñez, MS, CGC)
  • 7:45 - 8:20 AM - Topic 2: Navigating the Transition from Discovery to Market for Patient and Societal Benefit: Relevance to Women with Blood Disorders (Jodi Black, PhD, MMSc)
  • 8:20 - 8:55 AM - Topic 3: Women, Sickle Cell Disease and Bleeding Disorders: Solutions Through Telehealth (Curtis Lowry, MD and Roshni Kulkarni, MD)
  • 8:55 - 9:05 AM - BREAK

Novel Therapies: Impacting Adolescent Female and Maternal/Fetal Health

  • 9:05 - 9:40 AM - Topic 4: Maternal and Fetal Consequences of Rare Blood Disorders: Fibrinogen Deficiency, Factor XIII Deficiency and Inherited Platelet Disorders (Diane Nugent, MD)
  • 9:40 - 10:15 AM - Topic 5: Hydroxyurea and Pregnancy (Kim Smith-Whitley, MD)
  • 10:15 - 10:55 AM - Topic 6: Anticoagulation Update: A Focus on Issues Specific to Teenage Girls and Pregnant Women (Shannon Bates, MDCM, MSc)
  • 10:55 - 11:00 AM - Closing Remarks/Adjourn (Andra James, MD, MPH and Donna DiMichele, MD)

Discussants: Roshni Kulkarni, MD and Co-Chairs: Hematologic Solutions Through Telehealth.  Q&A will be included within each session. 

Activity Director, FWGBD President and Co-Chair

Andra H. James, MD, MPH
Duke University
Durham, North Carolina

Co-Chair, Moderator/Faculty in Presentation/Program Order:

Donna DiMichele, MD
Division of Blood Disorders and Resources
NHLBI, NIH
Bethesda, Maryland

Kristin Paulyson Nuñez, MS, CGC
Duke Comprehensive Center for Hemostasis and Thrombosis
Durham, NC

Jodi Black, PhD, MMSc
Division of Extramural Research Activities
NHLBI, NIH
Bethesda Maryland

Curtis Lowry, MD
The University of Arkansas for Medical Sciences
Little Rock, Arkansas

Roshni Kulkarni, MD
Michigan State University Center for Bleeding and Clotting Disorders
East Lansing, Michigan

Diane Nugent, MD
CHOC Orange & CHOC Mission
Orange, California

Kim Smith-Whitley, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Shannon Bates, MDCM, MSc
McMaster University
Hamilton, Ontario, CANADA

How to Receive CE Credit

Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 3.75 AMA PRA Category 1 CreditsPhysicians should only claim credit commensurate with the extent of their participation in the activity.

In order to receive CE credit, participants must sign-in at the registration desk, review the CE information (accreditation information, learning objectives, faculty disclosures, etc) and attend the Symposium. At the completion of the Symposium, an e-mail with instructions on how to access the online evaluation will be sent to participants to complete. Once the evaluation is complete, participants should attest credit and then follow the instructions to download their CE certificate. If you have any questions regarding CE credit, please contact the Duke Office of CE at (919) 401-1200.